Ablynx NV News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.03.16	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
14.03.16	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
07.03.16	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
25.02.16	ABLYNX ANNOUNCES 2015 FULL YEAR RESULTS (GlobeNewswire)
23.02.16	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
18.02.16	ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016 (GlobeNewswire)
11.02.16	NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ABLYNX'S PHASE II TITAN STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP (GlobeNewswire)
29.01.16	ABLYNX TO RECEIVE €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY (GlobeNewswire)
21.01.16	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
18.01.16	PERCEPTIVE ADVISORS LLC ANNOUNCE 5.06% SHAREHOLDING IN ABLYNX (GlobeNewswire)
07.01.16	ABLYNX TO PRESENT AT THE 34th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (GlobeNewswire)
05.01.16	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
22.12.15	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
17.12.15	ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS (GlobeNewswire)
16.12.15	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
09.12.15	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
02.12.15	JP MORGAN ASSET MANAGEMENT HOLDINGS ANNOUNCE 3.33% SHAREHOLDING IN ABLYNX (GlobeNewswire)
01.12.15	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
30.11.15	ABLYNX APPOINTS ROBERT K. ZELDIN, MD, CHIEF MEDICAL OFFICER (GlobeNewswire)
25.11.15	ABLYNX ANNOUNCES NANOBODY DRUG DISCOVERY COLLABORATION WITH NOVO NORDISK (GlobeNewswire)
18.11.15	ABLYNX PROVIDES BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2015 (GlobeNewswire)
05.11.15	ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EURO GLOBAL SUMMIT ON CANCER THERAPY (GlobeNewswire)
21.10.15	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
15.10.15	ABLYNX ACHIEVES FIRST MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC. (GlobeNewswire)
29.09.15	ABLYNX INITIATES A MULTINATIONAL PHASE III STUDY WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP, A RARE BLOOD CLOTTING DISORDER (GlobeNewswire)
27.08.15	ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015 (GlobeNewswire)
19.08.15	ABLYNX TO HOST WEBCAST FOR ITS 2015 HALF-YEAR RESULTS ON 27 AUGUST (GlobeNewswire)
14.08.15	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
04.08.15	ABLYNX INITIATES PHASE II SLE STUDY WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE (GlobeNewswire)
31.07.15	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
29.07.15	PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
22.07.15	ABLYNX SIGNIFICANTLY EXPANDS ITS IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC. (GlobeNewswire)
20.07.15	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
14.07.15	OPPENHEIMER FUNDS, INC. ANNOUNCE 3.07% SHAREHOLDING IN ABLYNX (GlobeNewswire)
01.07.15	TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 5.14% SHAREHOLDING IN ABLYNX (GlobeNewswire)
30.06.15	ABLYNX AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ANTI-TNFa NANOBODY (OZORALIZUMAB) IN JAPAN (GlobeNewswire)
17.06.15	ABLYNX ANNOUNCES PRESENTATIONS ON ITS POTENTIAL FIRST-IN-CLASS TREATMENT FOR ACQUIRED TTP, CAPLACIZUMAB, AT THE 2015 ANNUAL MEETING OF THE ISTH (GlobeNewswire)
05.06.15	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
28.05.15	ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE (GlobeNewswire)
26.05.15	FMR LLC ANNOUNCE 5.07% SHAREHOLDING IN ABLYNX (GlobeNewswire)
22.05.15	TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 4.35% SHAREHOLDING IN ABLYNX (GlobeNewswire)
18.05.15	GENZYME TO COLLABORATE WITH ABLYNX ON MULTIPLE SCLEROSIS RESEARCH PROJECT (GlobeNewswire)
13.05.15	ABLYNX ANNOUNCES BUSINESS UPDATE AND FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2015 (GlobeNewswire)
07.05.15	ABLYNX PRESENTS UNIQUE NANOBODY DRUG INHALATION TECHNOLOGY AT THE RESPIRATORY DRUG DELIVERY EUROPE 2015 CONFERENCE (GlobeNewswire)
21.04.15	ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
15.04.15	FMR LLC PROVIDE NOTIFICATION OF SHAREHOLDING IN ABLYNX (GlobeNewswire)
07.04.15	ABLYNX ANNOUNCES PUBLICATION OF 2014 ANNUAL REPORT AND LAUNCH OF NEW WEBSITE (GlobeNewswire)
07.04.15	ABLYNX INITIATES THE SECOND OF TWO PHASE IIb RA STUDIES WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE (GlobeNewswire)
26.03.15	ABLYNX ANNOUNCES EXTENSION OF ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC. (GlobeNewswire)
17.03.15	ABLYNX INITIATES THE FIRST OF TWO PHASE IIb RA STUDIES WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ablynx NV

Aktien Top/Flop

Meistgelesene Nachrichten